3D Printing Veteran Directs Aleph Objects European Operations
Driven by the continuous success of its award-winning LulzBot 3D Printer line, Aleph Objects, Inc. recently expanded into a new location within Europe, and is pleased to announce that Jeroen Wijnen has accepted the position of European Managing Director. Wijnen will provide 3D printing solutions for the specific needs of customers and resellers in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005988/en/
Jeroen Wijnen, Aleph Objects new European Managing Director, will facilitate the development of Aleph Objects Netherlands B.V. to provide 3D printing solutions for the specific needs of customers and resellers in Europe. (Photo: Business Wire)
Creating a Strong Presence
A veteran of 3D printing, Wijnen orchestrated Ultimaker’s product management team and launched Raise 3D in Europe. He brings nearly 20 years of experience in the high-tech industry and global marketing sector to his new role at Aleph Objects.
“Creating a strong presence for LulzBot to assist our existing and new customers and resellers in Europe is my first priority,” said Wijnen. “I’m convinced LulzBot’s dedication to reliability of its 3D printers and unrivaled customer support will be appealing to the European market. This will enable LulzBot to set new standards with the unveiling of upcoming product launches. I am excited to be part of the team.”
New European Headquarters
Aleph Objects announced the new European headquarters in Rotterdam, Netherlands, earlier this week. Strategically situated at the gateway to Europe, near The Hague, Aleph Objects Netherlands, B.V. will serve as a local presence for product demonstrations, support, and consulting.
Wijnen will facilitate the development of Aleph Objects Netherlands, B.V. He will also grow and manage all European LulzBot 3D Printer resellers, in addition to coordinating logistics and managing all European sales.
With the LulzBot product line’s award-winning reliability, the industry’s highest-rated technical support, and several exciting new products in 2019, revenue growth in the European market is expected to reach triple digits.
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers. LulzBot is a trusted brand in Automotive, Consumer Products, Aerospace/Defense, Medical, and Education industries around the globe. Aleph Object’s core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination to life. For more information, visit www.LulzBot.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005988/en/
Contact information
Jeroen Wijnen
European Managing Director
Aleph Objects
Netherlands B.V.
jeroen@alephobjects.com
mobile
number +31 6 50 213 123
Press Contact:
Hob Wubbena, VP
hob@alephobjects.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom